Scarica l'app Stockscreener
39.93
5.22%
1.98
Dopo l'orario di chiusura:
39.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$37.95
Aprire:
$38.13
Volume 24 ore:
1.70M
Relative Volume:
1.63
Capitalizzazione di mercato:
$3.13B
Reddito:
$1.55M
Utile/perdita netta:
$-258.76M
Rapporto P/E:
-10.25
EPS:
-3.8953
Flusso di cassa netto:
$-213.66M
1 W Prestazione:
+7.31%
1M Prestazione:
+39.52%
6M Prestazione:
+43.84%
1 anno Prestazione:
+90.32%
Intervallo 1D:
$37.30
$40.30
Intervallo di 1 settimana:
$36.17
$40.30
Portata 52W:
$19.72
$40.30
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
39.93 | 2.98B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Aggiornamento | Barclays | Underweight → Overweight |
| 2026-03-23 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-13 | Iniziato | Barclays | Underweight |
| 2025-04-28 | Iniziato | Canaccord Genuity | Buy |
| 2025-03-20 | Iniziato | Morgan Stanley | Overweight |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Celldex Therapeutics stock hits 52-week high at 39.16 USD - Investing.com
Price to sales forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed? - simplywall.st
Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus - Sahm
CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $54 - Moomoo
CLDX Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Pipeline ProgressEarnings Season Review - dars.gov.et
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval? - Yahoo Finance
Form 4 Celldex Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity - Stock Titan
Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Celldex (NASDAQ: CLDX) CCO granted 90,000 stock options at $34.09 - Stock Titan
Celldex (NASDAQ: CLDX) grants SVP & counsel 93,000 stock options - Stock Titan
Celldex (CLDX) CMO Diane Young receives 57,000 stock options grant - Stock Titan
Celldex (CLDX) SVP granted 95,000 options at $34.09 strike - Stock Titan
Celldex Therapeutics (CLDX) CFO awarded 93,000 stock options grant - Stock Titan
Celldex (CLDX) SVP awarded 95,000-share stock option grant at $34.09 - Stock Titan
Celldex (NASDAQ: CLDX) grants 100,000 options to senior VP & CPDO - Stock Titan
Celldex Therapeutics (CLDX) grants 20,000 stock options to senior VP - Stock Titan
Celldex (CLDX) EVP & CSO awarded 115,000-share stock option grant - Stock Titan
Celldex (CLDX) CEO Anthony Marucci receives grant of 375,000 stock options - Stock Titan
Celldex (CLDX) director awarded 26,000-share stock option grant as compensation - Stock Titan
Celldex (CLDX) director receives grant of 26,000 stock options - Stock Titan
Celldex (CLDX) director James Marino awarded options on 26,000 shares - Stock Titan
Celldex Therapeutics (CLDX) director receives grant of 26,000 stock options - Stock Titan
Celldex (CLDX) director receives 26,000 stock options under 2021 incentive plan - Stock Titan
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2500 Growth Benchmark - marketscreener.com
Celldex Therapeutics stock hits 52-week high at 35.8 USD - Investing.com
Celldex Therapeutics stock hits 52-week high at 35.8 USD By Investing.com - Investing.com South Africa
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 2000 Growth Benchmark - marketscreener.com
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 3000E Growth Benchmark - marketscreener.com
Celldex Therapeutics, Inc.(NasdaqCM: CLDX) added to Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
5 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Enterprise value to EBIT forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView
Enterprise value to EBITDA forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Enterprise value to EBITDA forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView
Price to earnings forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView
Enterprise value to revenue forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Price to book forward of Celldex Therapeutics, Inc. – SWB:TCE2 - TradingView
Celldex Shareholders Approve Expanded Equity Incentive Plan - TipRanks
Celldex (CLDX) shareholders back larger equity plan and all directors - Stock Titan
Celldex Therapeutics (CLDX) Is Up 5.1% After Barzolvolimab, CDX-622 Mast-Cell Data UpdateWhat's Changed - Sahm
Celldex Therapeutics, Inc. Actuals & Estimates (NASDAQ:CLDX) - TradingView
CLDX Forecast — Price Target — Prediction for 2027 - TradingView
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight - PR Newswire
Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data - Sahm
Chronic Spontaneous Urticaria Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart
Celldex Therapeutics Inc (CLDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Celldex Therapeutics Inc (CLDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Celldex Therapeutics Inc Azioni (CLDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PEPIN RONALD | SR. VP & CBO |
Dec 15 '25 |
Option Exercise |
5.47 |
19,333 |
105,714 |
20,097 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Dec 04 '25 |
Sale |
29.09 |
4,166 |
121,210 |
30,796 |
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):